SCHEMBL29384348

SCHEMBL29384348

O=C(Nc1ccc2cc(S(=O)(=O)O)cc(O)c2c1)Nc1ccc2cc(S(=O)(=O)O)cc(O)c2c1

nearest known ligand 0.81

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRMT1 Q99873 3/20 0.81
NT5E P21589 2/20 0.79
CASP6 P55212 4/20 0.66
NSD2 O96028 3/20 0.66
DUSP3 P51452 2/20 0.66
PTPN5 P54829 2/20 0.66
PTPN11 Q06124 2/20 0.66
CASP7 P55210 1/20 0.66
SIRT1 Q96EB6 1/20 0.59
CTDSP1 Q9GZU7 1/20 0.55
ENPP2 Q13822 2/20 0.51
CA2 P00918 1/20 0.50
ALDH1A1 P00352 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10900036 1.00 PRMT1 (0.81) PRMT1NT5ECASP6NSD2DUSP3
SCHEMBL16255037 0.92 PRMT1 (0.69) PRMT1NT5ECASP6NSD2DUSP3
SCHEMBL11211030 0.91 PRMT1 (0.67) PRMT1NT5ECASP6NSD2DUSP3
SCHEMBL11489790 0.90 PRMT1 (0.66) PRMT1NT5ECASP6NSD2DUSP3
SCHEMBL29349608 0.89 PRMT1 (1.00) PRMT1NT5ECASP6NSD2DUSP3
SCHEMBL2679101 0.89 PRMT1 (1.00) PRMT1NT5ECASP6NSD2DUSP3
SCHEMBL6079067 0.89 PRMT1 (1.00) PRMT1NT5ECASP6NSD2DUSP3
SCHEMBL8439783 0.88 NT5E (1.00) PRMT1NT5ECASP6NSD2DUSP3
SCHEMBL1803097 0.88 NT5E (0.75) PRMT1NT5ECASP6NSD2DUSP3
SCHEMBL10823488 0.88 PRMT1 (0.64) PRMT1NT5ECASP6NSD2DUSP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115280435-B Anisotropic rare earth sintered magnet and method for producing same 信越化学工业株式会社 2026-02-27 CN disclosed
US-12552882-B2 Polymeric disinfectants and uses thereof TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2026-02-17 US disclosed
US-20250387582-A1 PATIENT INTERFACE AND COMPONENT PARTS FISHER & PAYKEL HEALTHCARE LTD (NZ) 2025-12-25 US disclosed
US-12499971-B2 Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof THE BROAD INSTITUTE, INC. (US) 2025-12-16 US disclosed
EP-4237493-B1 POLYMERIC DISINFECTANTS AND USES THEREOF TECHNION RES & DEV FOUNDATION (IL) 2025-12-10 EP disclosed
US-20250346862-A1 METHODS FOR THE RE-DERIVATION OF DIVERSE PLURIPOTENT STEM CELL-DERIVED BROWN FAT CELLS AgeX Therapeutics,Inc. (US) 2025-11-13 US disclosed
US-12410116-B2 Compounds and use thereof in methods of treatment THE UNIVERSITY OF QUEENSLAND (AU) 2025-09-09 US disclosed
US-12404493-B2 Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells AGEX THERAPEUTICS, INC. (US) 2025-09-02 US disclosed
US-20250223579-A1 NOVEL CRISPR ENZYMES AND SYSTEMS BROAD INST INC (US) 2025-07-10 US disclosed
US-20250179453-A1 CRISPR ENZYME MUTATIONS REDUCING OFF-TARGET EFFECTS THE BROAD INSTITUTE, INC. (US) 2025-06-05 US disclosed
US-11591601-B2 Methods for identification and modification of lncRNA associated with target genotypes and phenotypes THE BROAD INSTITUTE, INC. (US) 2023-02-28 US disclosed
EP-4130301-A1 ANISOTROPIC RARE-EARTH SINTERED MAGNET AND METHOD FOR PRODUCING SAME Shin-Etsu Chemical Co., Ltd. (JP) 2023-02-08 EP disclosed
CN-115433707-A Method for the re-derivation of brown adipocytes derived from different pluripotent stem cells 再生疗法有限公司 2022-12-06 CN disclosed
EP-2838721-B9 METHOD FOR MANUFACTURING A SET OF EMBOSSING ROLLERS BOEGLI GRAVURES SA (CH) 2022-09-21 EP disclosed
US-11434190-B2 Inhibitors of SOX18 protein activity for treating angiogenesis-and/or lymphangiogenesis-related diseases THE UNIVERSITY OF QUEENSLAND (AU) 2022-09-06 US disclosed
CN-114930257-A Control device and method for controlling variable physical parameters 钟国诚 2022-08-19 CN disclosed
CN-110721383-B Patient interface and component 费雪派克医疗保健有限公司 2022-07-26 CN disclosed
WO-2022091091-A1 POLYMERIC DISINFECTANTS AND USES THEREOF TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2022-05-05 WO disclosed
CN-108779435-B Method for the re-derivation of different pluripotent stem cell-derived brown adipocytes 再生疗法有限公司 2022-05-03 CN disclosed
EP-3950673-A1 INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF Inspirna, Inc. (US) 2022-02-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11434190-B2 Inhibitors of SOX18 protein activity for treating angiogenesis-and/or lymphangiogenesis-related diseases SOX18, PROX1, RUNX1 PRMT1 2082/4885NT5E 3282/4885CASP6 3482/4885
US-20250387582-A1 PATIENT INTERFACE AND COMPONENT PARTS RAE1, EXOSC9, SET PRMT1 1408/4885NT5E 303/4885CASP6 3271/4885
US-12552882-B2 Polymeric disinfectants and uses thereof PIK3C3, POLR1C, CUTA PRMT1 1828/4885NT5E 2774/4885CASP6 1026/4885
US-12410116-B2 Compounds and use thereof in methods of treatment SOX18, PROX1, RUNX1 PRMT1 2285/4885NT5E 3125/4885CASP6 2999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.